Association between anti-TNF-α therapy and interstitial lung disease

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 4, 2013, Pages 394-402

  Herrinton, Lisa J ^a   Harrold, Leslie R ^b   Liu, Liyan ^a   Raebel, Marsha A ^c   Taharka, Ananse' ^d   Winthrop, Kevin L ^e   Solomon, Daniel H ^f   Curtis, Jeffrey R ^g   Lewis, James D ^h   Saag, Kenneth G ^g  

^a DIVISION OF RESEARCH   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c Kaiser Permanente Colorado   (United States)

^d KAISER PERMANENTE   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adverse events; Automated healthcare data; Cohort studies; Crohn's disease; Drug safety; Drug toxicity; Inflammatory bowel disease; Interstitial lung disease; Pharmacoepidemiology; Propensity scores; Psoriasis; Psoriatic arthritis; Pulmonary fibrosis; Rheumatoid arthritis; Ulcerative colitis

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CHILD; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DRUG INDUCED DISEASE; FEMALE; FOLLOW UP; HUMAN; INFANT; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SYSTEMATIC REVIEW; VALIDATION STUDY; X RAY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875805974     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3409     Document Type: Article

References (21)

1. Jones N, Schneider G, Kachroo S, Rotella P, Avetisyan R, Reynolds MW. A systematic review of validated methods for identifying pulmonary fibrosis and interstitial lung disease using administrative and claims data. Pharmacoepidemiol Drug Saf 2012 Jan;21 Suppl 1:256-60.
2. Grijalva Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Griffin MR, Herrinton L, Liu L, Nourjah P, Ouellet-Hellstrom R, Patkar NM, Solomon DH, Winthrop KL, Lewis JD, Xie F, Saag KG, Curtis JR. Initiation of biologic DMARDs and the risk of hospitalization for infection in patients with autoimmune disease. JAMA 2011 Dec 7;306(21):2331-9.
3. Herrinton LJ, Liu L, Chen L, Harrold LR, Raebel M, Curtis JR, Griffin MR, Solomon DH, Saag KG, Lewis JD. Association between anti-TNF-α therapy and all-cause mortality. Pharmacoepidemiology and Drug Saf 2012 Oct 15. doi: 10.1002/pds.3354. [Epub ahead of print]
4. Herrinton LJ, Curtis JR, Chen L, Liu L, Delzell E, Lewis JD, Solomon DH, Griffin MR, Quellet-Hellstom R, Beukelman T, Grijalva CG, Haynes K, Kuriya B, Lii J, Mitchel E, Patkar N, Rassen J, Winthrop KL, Nourjah P Saag KG. Study Design for a Comprehensive Assessment of Biologic Safety Using Multiple Healthcare Data Systems. Pharmacoepidemiol and Drug Saf, in press.
5. Ramos-Casals M, Perez-Alvarez R, Perez-de-Lis M, Xaubet A, Bosch X; BIOGEAS study group. Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases. Am J Med 2011 May;124(5):386-94.
6. de Lauretis A, Veeraraghavan S, Renzoni E. Review series: aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? Chron Respir Dis 2011;8(1):53-82.
7. Morganthau AS, Padilla MR. Spectrum of fibrosis diffuse parenchymal lung disease. Mt Sinai J Med 2001;76:2-23.
8. Gordon NP. "How does the adult Kaiser Permanente membership in Northern California compare with the larger community?" Reported dated June 14, 2006. http://www.dor.kaiser.org/external/uploadedFiles/content/research/mhs/_2011_Revised_Site/Documents_Special_Reports/comparison_kaiser_vs_nonKaiser_adults_kpnc(1).pdf Accessed June 27, 2011.
9. Brown LD, Cai TT, DasGupta A. Interval estimation for a binomial proportion. Statistical Science 2001; 16(2): 101-117.
10. Rassen JA, Solomon DH, Curtis JR, Herrinton L, Schneeweiss S. Privacy-maintaining propensity score-based pooling of multiple databases applied to a study of biologics. Med Care 2010 Jun;48(6 Suppl):S83-9.
11. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009 Jul;20(4):512-22.
12. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997 Oct 15;127(8 Pt 2):757-63.
13. Stürmer T, Schneeweiss S, Brookhart MA, Rothman KJ, Avorn J, Glynn RJ. Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol. 2005 May 1;161(9):891-8.
14. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. Journal of the American Statistical Association 1989;84:1074-1078.
15. Calabrese LH. Molecular differences in anticytokine therapies. Clin Exp Rheumatol (2003);21:241-248.
16. Wolfe F, Caplan L, Michaud K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scand J Rheumatol. 2007 May-Jun;36(3):172-8.
17. Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, Vassallo R, Gabriel SE, Matteson EL. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 2010 Jun;62(6):1583-91.
18. Dixon WG, Hyrich KL, Watson KD, Lunt M, BSRBR control centre consortium, Symmons DP, British Society for Rheumatology Biologics Register. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2010 Jun;69(6):1086-91.
19. Nannini C, Ryu JH, Matteson EL. Lung disease in rheumatoid arthritis. Current Opinion in Rheumatology 2008;20:340-346.
20. Amar RK, Jick SS, Rosenberg D, Maher TM, Meier CR. Drug-/radiation-induced interstitial lung disease in the United Kingdom general population: incidence, all-cause mortality and characteristics at diagnosis. Respirology 2012 Jul;17(5):861-8.
21. Gochuico BR, Avila NA, Chow CK, Novero LJ, Wu HP, Ren P, MacDonald SD, Travis WD, Stylianou MP, Rosas IO. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med 2008 Jan 28;168(2):159-66.